Actively Recruiting
Phase 1 Safety Study of CRD3874-SI Drug for Adults with Relapsed or Refractory Acute Myeloid Leukemia
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-06-22
24
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating CRD3874-SI, a STING agonist drug, as a potential treatment for adults with relapsed or refractory acute myeloid leukemia AML. This phase 1 study aims to determine the safety and maximum tolerated dose of CRD3874-SI in participants who have failed previous active AML therapies. The trial is led by Memorial Sloan Kettering Cancer Center and focuses on adults aged 18 years and older with this difficult-to-treat leukemia. Participants receive one of three doses of CRD3874-SI 0.6 mgkg, 0.9 mgkg, or 1.4 mgkg. The treatment is administered in a sequential manner and monitored closely to assess tolerance. The study evaluates dosage levels over a period of up to one year to find the maximum dose participants can safely tolerate. During the study, participants will undergo regular assessments including clinical evaluations and monitoring for side effects. Researchers will track the response to treatment and measure the maximum tolerated dose of CRD3874-SI up to one year. Participants are followed throughout the trial duration, which extends until June 2028, to carefully observe treatment effects and safety.
CONDITIONS
Brief Title
A Study of CRD3874-SI in People With Leukemia
Research Team
E
Eytan Stein, MD
A
Aaron Goldberg, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
